Navigation Links
Vanda Pharmaceuticals Reports Fourth Quarter and Full Year 2008 Results
Date:2/11/2009

tain the capital necessary to fund its research and development activities; Vanda's failure to identify or obtain rights to new product candidates; Vanda's failure to develop or obtain sales, marketing and distribution resources and expertise or to otherwise manage its growth; a loss of any of Vanda's key scientists or management personnel; losses incurred from product liability claims made against Vanda; a loss of rights to develop and commercialize Vanda's products under its license and sublicense agreements and other factors that are described in the "Risk Factors" section (Part II, Item 1A) of Vanda's quarterly report on Form 10-Q for the quarter ended September 30, 2008 (File No. 000-51863). In addition to the risks described above and in Part II, Item 1A of Vanda's quarterly report on Form 10-Q, other unknown or unpredictable factors also could affect Vanda's results. There can be no assurance that the actual results or developments anticipated by Vanda will be realized or, even if substantially realized, that they will have the expected consequences to, or effects on, Vanda. Therefore, no assurance can be given that the outcomes stated in such forward-looking statements and estimates will be achieved.

All written and verbal forward-looking statements attributable to Vanda or any person acting on its behalf are expressly qualified in their entirety by the cautionary statements contained or referred to herein. Vanda cautions investors not to rely too heavily on the forward-looking statements Vanda makes or that are made on its behalf. The information in this release is provided only as of the date of this release, and Vanda undertakes no obligation, and specifically declines any obligation, to update or revise publicly any forward-looking statements, whether as a result of new information, future events or otherwise.

                          VANDA PHARMACEUTICALS INC.
                      
'/>"/>
SOURCE Vanda Pharmaceuticals Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10

Related biology technology :

1. Vanda Pharmaceuticals Reports Third Quarter 2008 Results
2. Vanda Pharmaceuticals Declares Dividend Distribution of Preferred Stock Purchase Rights
3. Vanda Pharmaceuticals to Announce Second Quarter 2008 Financial Results on August 5, 2008
4. LabCorp(R) and Vanda Pharmaceuticals Collaborate to Offer Genetic Tests
5. Vanda Pharmaceuticals to Present at the Bank of America 2008 Healthcare Conference
6. Vanda Pharmaceuticals Reports Fourth Quarter and Full Year 2007 Results
7. Cadence Pharmaceuticals CEO Theodore Schroeder to Present at the Roth Capital Partners 21st Annual OC Growth Stock Conference
8. Sagent Pharmaceuticals Announces Expansion of Cefazolin Product Line to Include Cefazolin for Injection, USP in 500mg Single-Dose Vial
9. PacificGMP and LigoCyte Pharmaceuticals Announce cGMP Manufacturing Collaboration
10. Diffusion Pharmaceuticals Announces Completion of a $2.9 Million Private Placement and Company Presentations at Upcoming Industry Conferences in Geneva, Switzerland and Naples, Florida
11. Tigris Pharmaceuticals Files IND Application for GGTI-2418
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/19/2014)... BioPlus Specialty Pharmacy (BioPlus), one of ... Nick Maroulis, Pharm.D. to the newly created position of ... this position, Dr. Maroulis will continue to manage the ... our multi-site pharmacies as the company expands. Dr. Maroulis ... time he has served in many different capacities in ...
(Date:12/19/2014)... PLEASANTON, Calif. , Dec. 19, 2014  Roche ... acquisition of Bina Technologies, Inc. (Bina), a privately ... California , USA. Bina provides a big ... next generation sequencing (NGS) data. Bina,s proprietary on-market ... translational and academic researchers to perform fast and ...
(Date:12/19/2014)... , Dec. 19, 2014 Decision Resources Group ... grow at a 12 percent compound annual growth rate ... the aging population and the increasing adoption of dental ... will also spur demand for dental biomaterials ... implant and periodontal treatments. Other key findings ...
(Date:12/19/2014)... Springs, FL (PRWEB) December 18, 2014 ... of the nation’s leading specialty pharmacies, has an ... serve as clinical pharmacy consultants for prescriber offices ... therapy expertise. , “We have a variety ... therapies. For example, those specializing in hepatitis C ...
Breaking Biology Technology:BioPlus Specialty Pharmacy Promotes Dr. Nick Maroulis to Vice President of Specialty Pharmacy Services 2Roche acquires Bina Technologies and enters the genomic informatics market 2Roche acquires Bina Technologies and enters the genomic informatics market 3Latin American Dental Biomaterial Market Will Expand at a 12 Percent Annual Growth Rate Through 2023 2Latin American Dental Biomaterial Market Will Expand at a 12 Percent Annual Growth Rate Through 2023 3BioPlus Specialty Pharmacy Expands ‘Regional Pharmaceutical Care Liaison’ Team 2BioPlus Specialty Pharmacy Expands ‘Regional Pharmaceutical Care Liaison’ Team 3
... Economic Summit served its purpose by fading away. , ... place between 2000 and 2003 were unsuccessful; on the ... state's growth. But once those general themes were pinpointed, ... them, the Wisconsin Economic Summit needed to give way ...
... - There is nothing that could have been done ... Thursday. But thanks to technology, warning systems for such storms ... F3-grade tornadoes that swept through the south central and western ... of tornadoes here in one day and, undoubtedly, took many ...
... rules, the manufacturer's product going straight to the lap of the ... a roofer or a big business, a single-item purchase is sufficient. ... no costly structures, no bureaucracies and no extra hoards of people ... cheap -- it just takes one call and one quick delivery. ...
Cached Biology Technology:Forum builds on the work of the Wisconsin Economic Summit 2Forum builds on the work of the Wisconsin Economic Summit 3Tornadoes put technology to work 2Tornadoes put technology to work 3Tornadoes put technology to work 4Move over B2B, B2C -- it's M2E time 2Move over B2B, B2C -- it's M2E time 3
(Date:12/11/2014)... 10, 2014  Data Sciences International (DSI), the ... a new series of digital telemetry implants to ... M series, part of the PhysioTel™ Digital platform, ... possible physiologic data when incorporating functional endpoints into ... to toxicology studies has evolved from short ECG ...
(Date:12/10/2014)... DIEGO , Dec. 9, 2014 CIE ... collaboration catalyst that provides the connective tissue that enhances ... enabling them to easily share client-level information; earned a ... to expand to organizations serving seniors aging in community ... Diego" partner on December 11 th 4-6p. ...
(Date:12/5/2014)... , Dec. 4, 2014  Tute Genomics, a ... $2.3 million in Series A1 funding led by UK-based ... also participated in the investment round. "We ... healthcare community adopts next-generation sequencing and seeks new approaches ... Reid Robison , MD MBA, and CEO of ...
Breaking Biology News(10 mins):New telemetry implants expected to change how large animal toxicology studies are conducted 2Community Information Exchange San Diego Launches Pilot, Secures $1 Million Expansion Grant, and Becomes a "Live Well San Diego" Partner 2Community Information Exchange San Diego Launches Pilot, Secures $1 Million Expansion Grant, and Becomes a "Live Well San Diego" Partner 3Community Information Exchange San Diego Launches Pilot, Secures $1 Million Expansion Grant, and Becomes a "Live Well San Diego" Partner 4Tute Genomics Raises $2.3 Million to Scale Up Cloud-Based Genome Analytics and Accelerate Personalized Medicine 2Tute Genomics Raises $2.3 Million to Scale Up Cloud-Based Genome Analytics and Accelerate Personalized Medicine 3
... at four major genomics and plant pathology laboratories in ... causative agent of "black rot" disease, which is the ... which represents the largest comparative and functional genomics screen ... is published online today in the journal Genome Research. ...
... the toxins that cause paralytic shellfish poisoning (PSP), but scientists ... protection. PSP toxins interfere with nerve function, and the mutation, ... makes nerves less sensitive to those toxins. , The discovery ... Nature. The authors suggest that it has wide ranging implications ...
... especially when it comes to the vaccine description; be sure ... want to understand what the vaccine is about. , ... The European Vaccine Effort against HIV/AIDS today announced that a ... and NYVAC-HIV-C for the prevention of HIV infection has started ...
Cached Biology News:Scientists identify genes responsible for 'black rot' disease in vegetables 2Mutation in clams protects against paralytic shellfish poisoning but raises human health risk 2'EuroVacc 02' HIV Vaccine Trial Begins 2'EuroVacc 02' HIV Vaccine Trial Begins 3
...
... of systems provide fast and reliable scalable ... proteomics and drug development laboratories. Staccato systems ... Workstation Series, Application Series and Custom Systems ... a remarkably compact system for performing ELISA ...
... low-vibration filter/fan unit provides continuous vertical flow ... 100 (ISO 5) cleanliness standards , ... clean and disinfect , Large, ... to allow insertion of filling machines or ...
... provides a safe, clean environment for ... accord with USP-797 requirements. HEPA filtration ... cleanliness conditions in the work area. ... tilt-up front panel for easy access ...
Biology Products: